t and the Becton Dickinson GeneOhm MRSA PCR sold by BD Diagnostics. The researchers concluded that the Detect-Ready MRSA assay is superior to the GeneOhm panel in terms of specificity, while still providing a more rapid screening service compared to traditional microbiology culture methods.*
Detect-Ready kits are compatible with a number of the real time-PCR platforms currently found in most hospitals. Samples for testing are simple to obtain using nasal swabs and the kit's ready-to-use pre-mixed reagents require only the addition of patient sample to run the test, which provides results in less than three hours. Unlike other tests that require special handling, Detect-Ready kits are off-the-shelf room temperature-stabilized and require no refrigeration.
The Detect-Ready MRSA Panel is currently available in the UK, Germany, Ireland, Switzerland, Spain, Austria, the Netherlands, Belgium, Luxembourg, Australia and Israel, and is in late-stage development in the US.
To learn more about the Detect-Ready MRSA Panel at ECCMID, visit Launch Diagnostics, MDI's distributor for the UK, France and Ireland, at Booth 577, or Alere, MDI's distributor for Germany, Austria and Switzerland, at Booth 615, or visit www.detect-ready.com.
The 22nd European Congress of Clinical Microbiology and Infectious Diseases will be held in London, UK from March 31 to April 3, 2012. For more information, visit www.congrex.ch/eccmid2012/home.html.
* A Comparative Study of Two MRSA PCR Assays, Sarah L. White, Eugene P. Halligan, Penelope R. Cliff Infection Sciences, GSTS Pathology, St. Thomas' Hospital, London, UK, 2011.
About Molecular Detection
Molecular Detection Inc. (MDI), a US-based company with offices in Wayne, PA, Tunbridge Wells, UK and Jerusalem, Israel, is developing and commercializing a port
Page: 1 2 3 Related medicine technology :1
|SOURCE Molecular Detection Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery2
. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics3
. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference4
. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award5
. Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics6
. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference7
. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)8
. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases9
. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway10
. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility11
. Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice